DOCSLIB.ORG

ICD-10-CM C&M September 2016 Diagnosis Agenda

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ICD-10-CM C&M September 2016 Diagnosis Agenda ICD-10 Coordination and Maintenance Committee Meeting September 13-14, 2016 Diagnosis Agenda Welcome and announcements Donna Pickett, MPH, RHIA Co-Chair, ICD-10 Coordination and Maintenance Committee Diagnosis Topics: Contents Abnormality in Fetal Heart Rate or Rhythm ................................................................................ 12 Traci Ramirez Acute Appendicitis .............................................................................................................................. 14 David Berglund, MD Acute Respiratory Distress ................................................................................................................ 17 Cheryl Bullock All-terrain-vehicles (ATVs) and motor-cross/dirt bikes........................................................... 18 Cheryl Bullock Amyloidosis ........................................................................................................................................... 21 David Berglund, MD Rito Bergemann, MD, PhD, MBA Director, Value Evidence Lead Rare Diseases,GlaxoSmithKline Amyotrophic Lateral Sclerosis (ALS) ........................................................................................... 25 Donna Pickett Antenatal Screening ............................................................................................................................ 26 Traci Ramirez Atrial Fibrillation ................................................................................................................................. 28 David Berglund, MD Avoidant/Restrictive Food Intake Disorder ................................................................................. 30 Cheryl Bullock Michael B. First, M.D., Professor of Clinical Psychiatry, Columbia University, New York American Psychiatric Association , DSM-5 Editorial and Coding Consultant ICD-10 Coordination and Maintenance Committee Meeting September 13-14, 2016 Body Integrity Dysphoria .................................................................................................................. 31 Donna Pickett Michael B. First, M.D., Professor of Clinical Psychiatry, Columbia University, New York Cholangitis with Cholecystitis in Cholelithiasis...................................................................... 36 David Berglund, MD Classification of Types of Myocardial Infarction....................................................................... 38 David Berglund, MD Contact with Birds: Psittacines (Parrot) ........................................................................................ 42 Donna Pickett Michael B. First, M.D., Professor of Clinical Psychiatry, Columbia University, New York Disorders of the Gallbladder and Biliary Tract ........................................................................... 43 David Berglund, MD Diverticular Disease of Intestine ..................................................................................................... 54 David Berglund, MD Dyspnea Crisis ...................................................................................................................................... 58 David Berglund, MD Factitious Disorder .............................................................................................................................. 59 Cheryl Bullock Michael B. First, M.D., Professor of Clinical Psychiatry, Columbia University, New York American Psychiatric Association, DSM-5 Editorial and Coding Consultant Gingival recession ............................................................................................................................... 61 Shannon McConnell Lamptey Heart Failure Classification .............................................................................................................. 62 David Berglund, MD Hepatic Encephalopathy .................................................................................................................... 66 ShannonMcConnell Lamptey Hypoxic ischemic encephalopathy [HIE] ..................................................................................... 70 Cheryl Bullock Infection Following a Procedure ..................................................................................................... 71 Cheryl Bullock Injury of optic tract and visual cortex ............................................................................................ 73 Cheryl Bullock Intestinal Obstruction .......................................................................................................................... 74 Shannon McConnell Lamptey Intracranial Injury ................................................................................................................................ 76 Traci Ramirez Mastocytosis and Certain Other Mast Cell Disorders ............................................................... 77 David Berglund, MD Multiple Pregnancy - Triplets and Above - Amnion and Chorion Equal to Fetus Number81 Cheryl Bullock 2 ICD-10 Coordination and Maintenance Committee Meeting September 13-14, 2016 Myopic Choroidal Neovascularization .......................................................................................... 84 Shannon McConnell Lamptey Michael X Repka, M.D., MBA Medical Director of Government Affairs American Academy of Ophthalmology Obsessive-Compulsive Disorders ................................................................................................... 87 Cheryl Bullock Michael B. First, M.D., Professor of Clinical Psychiatry, Columbia University, New York American Psychiatric Association, DSM-5 Editorial and Coding Consultant Post Endometrial Ablation Syndrome ........................................................................................... 88 Traci Ramirez Pulmonary Hypertension ................................................................................................................... 89 David Berglund, MD Scott Manaker, MD, PhD, Professor of Medicine, University of Pennsylvania Sickle Cell without Acute Chest Syndrome or Splenic Sequestration ................................. 93 Cheryl Bullock Spinal Stenosis with Neurogenic Claudication ........................................................................... 95 Shannon McConnell Lamptey Umbilical Granuloma in the Perinatal Period ......................................................................... 96 Cheryl Bullock Zika Related Newborn Conditions.................................................................................................. 97 Donna Pickett ICD-10-CM TABULAR LIST OF DISEASES - PROPOSED ADDENDA ..................... 99 ICD-10-CM INDEX LIST OF DISEASES - PROPOSED ADDENDA .......................... 109 3 ICD-10 Coordination and Maintenance Committee Meeting September 13-14, 2016 ICD-10 TIMELINE A timeline of important dates in the ICD-10 process is described below: September 13 –14, ICD-10 Coordination and Maintenance Committee 2016 meeting. Those who wish to attend the ICD-10 Coordination and Maintenance Committee meeting must have registered for the meeting online by September 2, 2016. You must bring an official form of picture identification (such as a driver’s license) in order to be admitted to the building. October 2016 Webcast of the September 13–14, 2016 ICD-10 Coordination and Maintenance Committee meeting will be posted on the CMS webpage as follows: https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/m eetings.html The webcast and video of the September 13–14, 2016 ICD-10 Coordination and Maintenance Committee meeting will be posted on CMS Youtube channel, at the link below. https://www.youtube.com/user/CMSHHSgov October 1, 2016 New and revised ICD-10-CM and ICD-10-PCS codes go into effect along with DRG changes. Final addendum available on web pages as follows: Diagnosis addendum - http://www.cdc.gov/nchs/icd/icd10cm.htm Procedure addendum – http://www.cms.gov/Medicare/Coding/ICD10/ October 16, 2016 Deadline for receipt of public comments on proposed new codes discussed at the September 13-14, 2016 ICD-10 Coordination and Maintenance Committee meetings for implementation on April 1, 2017. November 2016 Any new ICD-10 codes required to capture new technology that will be implemented on the following April 1 will be announced. Information on any new codes to be implemented April 1, 2017 will be posted on the following websites: http://www.cdc.gov/nchs/icd/icd10cm.htm http://www.cms.gov/Medicare/Coding/ICD10/ November 13, 2016 Deadline for receipt of public comments on proposed new codes and revisions discussed at the September 13-14, 2016 ICD-10 4 ICD-10 Coordination and Maintenance Committee Meeting September 13-14, 2016 Coordination and Maintenance Committee meetings for implementation on October 1, 2017. January 6, 2017 Deadline for requestors: Those members of the public requesting that topics be discussed at the March 7–8, 2017 ICD-10 Coordination and Maintenance Committee meeting must have their requests submitted to CMS for procedures and NCHS for diagnoses by this date. February 2017 Tentative agenda for the Procedure part of the March 7, 2017 ICD-10 Coordination and Maintenance Committee meeting posted on CMS webpage as follows: https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/IC D-9-CM-C-and-M-Meeting-Materials.html Tentative agenda for the Diagnosis part of the March 8, 2017 ICD-10 Coordination and Maintenance Committee meeting posted on NCHS homepage as follows: http://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm Federal Register
Load more

Recommended publications
  • Cardiac Amyloidosis
    Cardiac Amyloid: Contemporary Approach to Diagnosis and Advances in Treatment Cardiac Nursing Symposium October 17, 2019 Dana Miller AGPCNP-BC, CHFN The University of Kansas Medical Center Heart Failure Nurse Practitioner Oc Octob Learning objectives • Describe the different types of cardiac amyloidosis (Disease) • Recognize clinical manifestations of cardiac amyloidosis • Implement strategies for diagnosis of cardiac amyloidosis (Diagnosis) • Utilize recent clinical evidence for decisions about treatment of cardiac amyloidosis (Drugs and devices) What is the disease amyloidosis? • First described by Rudolf Virchow in 1858 describing the reaction of tissue deposits with iodine and sulfuric acid. • A disorder of misfolded proteins • Proteins circulate in the bloodstream and perform many functions in the body • Should be dissolved, in other words, liquid • In amyloid they become solid and deposit in organs and tissues in the body and cause problems Red flags for Cardiac Amyloidosis • Echocardiography • Low voltage on ECG and thickening of the septum/posterior wall>1.2 cm (unexplained increase in thickness) • Thickening of the RV free wall, valves Intolerance to bet blockers or ACEI Low normal BP inpatients with a previous history of HTN Donnelly and Hanna, 2017 JACC 2014 Red flags for AL • HFpEF + Nephrotic syndrome • Macroglossia and/or periorbital purpura • Orthostatic hypotension • Peripheral neuropathy • MGUS • Donnelly and Hanna, 2017 Red flags for ATTR • White male age>60 with HFpEF + history of carpal tunnel syndrome and or/spinal
    [Show full text]
  • Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions? Cheryl Lynn Smith
    Claremont Colleges Scholarship @ Claremont CMC Senior Theses CMC Student Scholarship 2018 Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions? Cheryl Lynn Smith Recommended Citation Smith, Cheryl Lynn, "Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions?" (2018). CMC Senior Theses. 1978. http://scholarship.claremont.edu/cmc_theses/1978 This Open Access Senior Thesis is brought to you by Scholarship@Claremont. It has been accepted for inclusion in this collection by an authorized administrator. For more information, please contact [email protected]. Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions? A Thesis Presented by Cheryl Lynn Smith To the Keck Science Department Of Claremont McKenna, Pitzer, and Scripps Colleges In partial fulfillment of The degree of Bachelor of Arts Senior Thesis in Human Biology 04/23/2018 LIFETIME PREVALENCE AND PROGNOSIS OF SCHIZOPHRENIA 1 Table of Contents Abstract …………………………………………………………...……………………… 2 1. Introduction………………………………………………...…………...……………… 3 2. Background Information ……………………………...……………………………….. 5 2.1 Historical Background of Schizophrenia ……………………....…………… 5 2.2 Lifetime Prevalence of Schizophrenia …………………………...…..……… 12 2.3 Prognosis in People with Schizophrenia ……………....………...…..……… 13 3. Methods …………………………………………...……………………..……………. 17 4. Results ……………………………………………...…………………….…….…….... 18 5. Discussion ……………………………………………...……………………………… 24 6. Acknowledgements …………………………………………...……………………….
    [Show full text]
  • Diseases/Symptoms Reported to Be Associated with Lyme Disease
    Diseases/Symptoms Reported to be Associated with Lyme Disease Abdominal pseudo-eventration Abdominal wall weakness Acrodermatitis chronica atrophicans (ACA) Acute Acral Ischemia Acute conduction disorders Acute coronary syndrome Acute exogenous psychosis Acute febrile illness Acute hemiparesis Acute ischaemic pontine stroke Acute meningitis Acute myelo-meningo-radiculitis Acute myelitis Acute pediatric monoarticular arthritis Acute peripheral facial palsy Acute perimyocarditis Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) Acute pyogenic arthritis Acute reversible diffuse conduction system disease Acute septic arthritis Acute severe encephalitis Acute transitory auriculoventricular block Acute transverse myelitis Acute urinary retention Acquired Immune Deficiency Syndrome (AIDS) Algodystrophy Allergic conditions Allergic conjunctivitis Alopecia Alzheimer’s Disease Amyotrophic lateral sclerosis (ALS - Lou Gehrig's Disease) Amyotrophy Anamnesis Anetoderma Anorexia nervosa Anterior optic neuropathy Antepartum fever Anxiety Arrhythmia Arthralgia Arthritis Asymmetrical hearing loss Ataxic sensory neuropathy Atraumatic spontaneous hemarthrosis Atrioventricular block Attention Deficit Disorder (ADD) Attention Deficit Hyperactivity Disorder (ADHD) Back pain without radiculitis Bannwarth’s Syndrome Behcet's disease Bell’s Palsy Benign cutaneous lymphocytoma Benign lymphocytic infiltration (Jessner-Kanof) Bilateral acute confluent disseminated choroiditis Bilateral carpal tunnel syndrome Bilateral facial nerve palsy Bilateral
    [Show full text]
  • ICD-10-CM TABULAR LIST of DISEASES and INJURIES 2018 Addenda No Change Chapter 1 No Change Certain Infectious and Parasitic Diseases (A00-B99)
    ICD-10-CM TABULAR LIST of DISEASES and INJURIES 2018 Addenda No Change Chapter 1 No Change Certain infectious and parasitic diseases (A00-B99) No Change Intestinal infectious diseases (A00-A09) No Change A04 Other bacterial intestinal infections No Change A04.7 Enterocolitis due to Clostridium difficile Add A04.71 Enterocolitis due to Clostridium difficile, recurrent Add A04.72 Enterocolitis due to Clostridium difficile, not specified as recurrent No Change A05 Other bacterial foodborne intoxications, not elsewhere classified No Change Excludes1: Revise from Clostridium difficile foodborne intoxication and infection (A04.7) Revise to Clostridium difficile foodborne intoxication and infection (A04.7-) No Change Helminthiases (B65-B83) No Change B81 Other intestinal helminthiases, not elsewhere classified No Change Excludes1: Revise from angiostrongyliasis due to Parastrongylus cantonensis (B83.2) Revise to angiostrongyliasis due to: Add Angiostrongylus cantonensis (B83.2) Add Parastrongylus cantonensis (B83.2) No Change B81.3 Intestinal angiostrongyliasis Revise from Angiostrongyliasis due to Parastrongylus costaricensis Revise to Angiostrongyliasis due to: Add Angiostrongylus costaricensis Add Parastrongylus costaricensis No Change Chapter 2 No Change Neoplasms (C00-D49) No Change Malignant neoplasms of ill-defined, other secondary and unspecified sites (C76-C80) No Change C79 Secondary malignant neoplasm of other and unspecified sites Delete Excludes2: lymph node metastases (C77.0) No Change C79.1 Secondary malignant neoplasm of bladder
    [Show full text]
  • EFFECTIVE NEBRASKA DEPARTMENT of 01/01/2017 HEALTH and HUMAN SERVICES 173 NAC 1 I TITLE 173 COMMUNICABLE DISEASES CHAPTER 1
    EFFECTIVE NEBRASKA DEPARTMENT OF 01/01/2017 HEALTH AND HUMAN SERVICES 173 NAC 1 TITLE 173 COMMUNICABLE DISEASES CHAPTER 1 REPORTING AND CONTROL OF COMMUNICABLE DISEASES TABLE OF CONTENTS SECTION SUBJECT PAGE 1-001 SCOPE AND AUTHORITY 1 1-002 DEFINITIONS 1 1-003 WHO MUST REPORT 2 1-003.01 Healthcare Providers (Physicians and Hospitals) 2 1-003.01A Reporting by PA’s and APRN’s 2 1-003.01B Reporting by Laboratories in lieu of Physicians 3 1-003.01C Reporting by Healthcare Facilities in lieu of Physicians for 3 Healthcare Associated Infections (HAIs) 1-003.02 Laboratories 3 1-003.02A Electronic Ordering of Laboratory Tests 3 1-004 REPORTABLE DISEASES, POISONINGS, AND ORGANISMS: 3 LISTS AND FREQUENCY OF REPORTS 1-004.01 Immediate Reports 4 1-004.01A List of Diseases, Poisonings, and Organisms 4 1-004.01B Clusters, Outbreaks, or Unusual Events, Including Possible 5 Bioterroristic Attacks 1-004.02 Reports Within Seven Days – List of Reportable Diseases, 5 Poisonings, and Organisms 1-004.03 Reporting of Antimicrobial Susceptibility 8 1-004.04 New or Emerging Diseases and Other Syndromes and Exposures – 8 Reporting and Submissions 1-004.04A Criteria 8 1-004.04B Surveillance Mechanism 8 1-004.05 Sexually Transmitted Diseases 9 1-004.06 Healthcare Associated Infections 9 1-005 METHODS OF REPORTING 9 1-005.01 Health Care Providers 9 1-005.01A Immediate Reports of Diseases, Poisonings, and Organisms 9 1-005.01B Immediate Reports of Clusters, Outbreaks, or Unusual Events, 9 Including Possible Bioterroristic Attacks i EFFECTIVE NEBRASKA DEPARTMENT OF
    [Show full text]
  • Recent Advances in the Diagnosis and Management of Amyloid Cardiomyopathy
    Faculty Opinions Faculty Reviews 2021 10:(31) Recent advances in the diagnosis and management of amyloid cardiomyopathy Petra Nijst 1,2 W.H. Wilson Tang 3* 1 Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium 2 Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium 3 Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA Abstract Amyloidosis is a disorder characterized by misfolded precursor proteins that form depositions of fibrillar aggregates with an abnormal cross-beta-sheet conformation, known as amyloid, in the extracellular space of several tissues. Although there are more than 30 known amyloidogenic proteins, both hereditary and non-hereditary, cardiac amyloidosis (CA) typically arises from either misfolded transthyretin (ATTR amyloidosis) or immunoglobulin light-chain aggregation (AL amyloidosis). Its prevalence is more common than previously thought, especially among patients with heart failure and preserved ejection fraction (HFpEF) and aortic stenosis. If there is a clinical suspicion of CA, focused echocardiography, laboratory screening for the presence of a monoclonal protein (serum and urinary electrophoresis with immunofixation and serum free light-chain ratio), and cardiac scintigraphy with 99mtechnetium-labeled bone-tracers are sensitive and specific initial diagnostic tests. In some cases, more advanced/invasive techniques are necessary and, in the last several years, treatment options for both AL CA and ATTR CA have rapidly expanded. It is important to note that the aims of therapy are different. Systemic AL amyloidosis requires treatment targeted against the abnormal plasma cell clone, whereas therapy for ATTR CA must be targeted to the production and stabilization of the TTR molecule.
    [Show full text]
  • Preventable Diseases Nick Wilson, Michael G Baker Abstract New Zealanders Can Now Reflect on and Celebrate 50 Years of Polio Elimination in This Country
    THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Celebrating 50 years of polio elimination in New Zealand: but inadequate progress in eliminating other vaccine- preventable diseases Nick Wilson, Michael G Baker Abstract New Zealanders can now reflect on and celebrate 50 years of polio elimination in this country. This success was followed by eliminating two other infectious diseases, brucellosis and hydatids, and an imported potential disease vector, the southern saltmarsh mosquito. However, this country has made inadequate progress in eliminating several other vaccine-preventable diseases. These include measles, mumps, and rubella, which are priority candidates for elimination, and potentially Hib disease and rotavirus infection. To achieve such successes almost certainly requires that the country: (i) builds national leadership for elimination goals; (ii) develops detailed plans; (iii) continues recent successes in enhancing routine vaccination coverage; (iv) introduces rotavirus vaccine into the childhood immunisation schedule; and (v) strengthens surveillance and research (on such questions as the cost-effectiveness of new vaccines, measures to enhance uptake, and effective border controls to reduce the risk of disease importation). For 50 years now (since 1 April 1962), New Zealand has been free of transmission of wild-type polio virus infection. The end of this disease was particularly sudden with cases declining from 214 notifications in an outbreak in 1961 (with seven deaths) to only five cases in early 1962. 1 The end coincided with mass immunisation campaigns with the new Sabin (oral) vaccine in 1961 and 1962. The coverage in the vaccination campaign running from April to June 1962 was approximately 95% of the child population up to school leaving age.
    [Show full text]
  • The Healthcare System in Saudi Arabia and Its Challenges: the Case of Diabetes Care Pathway
    Journal of Health Informatics in Developing Countries www.jhidc.org Vol. 10 No. 1, 2016 Submitted: October 6, 2015 Accepted: January 17, 2016 The Healthcare System in Saudi Arabia and its Challenges: The Case of Diabetes Care Pathway Sarah Hamad ALKADI King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia Abstract. The advances of Information Technology (IT) play an important role globally in improving quality and capacity of healthcare sector. IT helps the health professions in managing resources and increasing productivity effectively. Although the conversion from paper to electronic patient records (EPR) conveys many benefits for both caregivers and caretakers, but also has brought many challenges in different aspects. Hospitals have implemented EPR to different degrees. They have used a set of standards in order to insure that data is accurately and consistently processed. Even though, the standardization of how data are captured, exchanged and used includes a set of complications that should be discovered to provide better health data quality for patients with multiple healthcare providers. Therefore, through an analysis of the EPR systems utilization in Saudi Arabia and the diabetes care pathway, three factors have been determined. These factors affect the workflow of the implementation and utilization of health information system (HIS) in terms of capturing, sharing and using its data efficiently. Keywords. HIS, EPR, information sharing, social factors, standards, health information management, diabetes care pathway, health informatics, data capturing, data sharing, Saudi Arabia. 1. Introduction The technology investment in health sector has importance in the management of healthcare services delivery in the developing countries. It is necessary to enhance the utilization as well as the implementation of HIS through standardizing the medical data in order to have a better data quality and more reliable system.
    [Show full text]
  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)—
    BIOEQUIVALENCE / VYNDALINK / REFS When you’ve decided VYNDAMAX is appropriate for your patient, VyndaLink may be able to help ATTR-CM is a progressive, fatal Enroll your patients in VyndaLink for support or send prescriptions directly to an in-network Specialty Pharmacy disease—recognize the signs The VyndaLink team can: and symptoms to diagnose and treat 2,3 Conduct a benefits verification to Determine payer requirements and Identify Specialty Pharmacy options based your appropriate patients determine your patient’s coverage provide information about the prior on your patient’s insurance coverage. Transthyretin amyloid for VYNDAMAX, including out-of- authorization process and appeals VYNDAMAX is available through multiple pocket costs. process as needed.* Specialty Pharmacies in our defined distribution network. VYNDAMAX—once-daily, oral medication for patients with wild-type or hereditary ATTR-CM *Please note where a PA is required, the physician must submit required information directly to the patient’s insurer. cardiomyopathy (ATTR-CM)— Get started at www.VyndaLink.com a disease that may be present in Download the enrollment form. Completed form can be sent online at www.VyndaLinkPortal.com or Proven to reduce mortality and 1 AM PM patients with heart failure faxed to 1-888-878-8474. Call 1-888-222-8475 (Monday-Friday, 8 -8 ET) with any questions. CV-related hospitalization Consider prescribing oral VYNDAMAX for References: 1. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571-579. 2. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid bril proteins and amyloidosis: chemical identication and clinical classication International Society of Amyloidosis 2016 Nomenclature Guidelines.
    [Show full text]
  • A Guide to Transthyretin Amyloidosis
    A Guide to Transthyretin Amyloidosis Authored by Teresa Coelho, Bo-Goran Ericzon, Rodney Falk, Donna Grogan, Shu-ichi Ikeda, Mathew Maurer, Violaine Plante-Bordeneuve, Ole Suhr, Pedro Trigo 2016 Edition Edited by Merrill Benson, Mathew Maurer What is amyloidosis? Amyloidosis is a systemic disorder characterized by extra cellular deposition of a protein-derived material, known as amyloid, in multiple organs. Amyloidosis occurs when native or mutant poly- peptides misfold and aggregate as fibrils. The amyloid deposits cause local damage to the cells around which they are deposited leading to a variety of clinical symptoms. There are at least 23 different proteins associated with the amyloidoses. The most well-known type of amyloidosis is associated with a hematological disorder, in which amyloid fibrils are derived from monoclonal immunoglobulin light-chains (AL amyloidosis). This is associated with a clonal plasma cell disorder, closely related to and not uncommonly co-existing with multiple myeloma. Chronic inflammatory conditions such as rheumatoid arthritis or chronic infections such as bronchiectasis are associated with chronically elevated levels of the inflammatory protein, serum amyloid A, which may misfold and cause AA amyloidosis. The hereditary forms of amyloidosis are autosomal dominant diseases characterized by deposition of variant proteins, in dis- tinctive tissues. The most common hereditary form is transthyretin amyloidosis (ATTR) caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently re- sult in instability of TTR and subsequent fibril formation. Closely related is wild-type TTR in which the native TTR protein, particu- larly in the elderly, can destabilize and re-aggregate causing non- familial cases of TTR amyloidosis.
    [Show full text]
  • Cardiac Amyloidosis
    Cardiac Amyloidosis Ronald Witteles, MD Stanford University & Brendan M. Weiss, MD University of Pennsylvania Amyloidosis: What is it? • Amylum – Starch (Latin) • Generic term for many diseases: • Protein misfolds into β-sheets • Forms into 8-10 nm fibrils • Extracellular deposition into amyloid deposits Types of Amyloid – Incomplete List • Systemic: • Light chains (AL) – “Primary ” • Transthyretin (ATTR) – “Senile ” or “Familial ” or “FAC” or “FAP” • Serum amyloid A (AA) – “Secondary ” • Localized – Not to be memorized! • Beta-2 microglobulin (A-β2) – Dialysis (osteoarticular structures) • Apolipoprotein A-1 (AApoA-I) – Age-related (aortic intima, cardiac, neuropathic) • Apolipoprotein A-2 (AApoA-2) – Hereditary (kidney) • Calcitonin (ACal) – Complication of thyroid medullary CA • Islet amyloid polypeptide (AIAPP) – Age-related (seen in DM) • Atrial natriuretic peptide (AANF) – Age-related (atrial amyloidosis) • Prolactin (APro) – Age-related, pituitary tumors • Insulin (AIns) – Insulin-pump use (local effects) • Amyloid precursor protein (ABeta) – Age-related/hereditary (Alzheimers) • Prion protein (APrPsc) – Hereditary/sporadic (spongiform encephalopathies) • Cystatin-C (ACys) – Hereditary (cerebral hemorrhage) • Fibrinogen alpha chain (AFib) – Hereditary (kidney) • Lysozome (ALys) – Hereditary (Diffuse, especially kidney, spares heart) • Medin/Lactadherin – Age-related (medial aortic amyloidosis) • Gelsolin (AGel) – Hereditary (neuropathic, corneal) • Keratin – Cutaneous AL: A Brief Dive into Hematology… Plasma cells: Make antibodies
    [Show full text]
  • Chapter DHS 146 VACCINE−PREVENTABLE DISEASES
    Published under s. 35.93, Wis. Stats., by the Legislative Reference Bureau. 271 DEPARTMENT OF HEALTH SERVICES DHS 146.04 Chapter DHS 146 VACCINE−PREVENTABLE DISEASES DHS 146.01 Authority and purpose. DHS 146.03 Vaccine−preventable diseases. DHS 146.02 Definitions. DHS 146.04 Purchase and distribution of vaccines. Note: Chapter HSS 146 was created as an emergency rule effective August 25, (8) Meningitis. 1994. Chapter HSS 146 was renumbered chapter HFS 146 under s. 13.93 (2m) (b) 1., Stats., Register, November, 1996, No. 491. Chapter HFS 146 was renumbered (9) Mumps. chapter DHS 146 under s. 13.92 (4) (b) 1., Stats., and corrections made under s. 13.92 (10) Pertussis (whooping cough). (4) (b) 7., Stats., Register January 2009 No. 637. (11) Pneumococcal. DHS 146.01 Authority and purpose. This chapter is (12) Poliomyelitis. promulgated under the authority of s. 252.04 (1) and (10), Stats., (13) Rabies. to specify vaccine−preventable diseases in addition to those listed (14) Rotavirus. in s. 252.04 (1), Stats. The department is directed by s. 252.04 (1), Stats., to carry out a statewide immunization program to eliminate (15) Rubella (German measles). vaccine−preventable diseases or otherwise protect people from (16) Tetanus. them, and by s. 252.04 (8), Stats., to provide vaccines without (17) Varicella (chickenpox). charge to immunize people against those diseases, if federal or (18) Zoster (shingles). state funds are available to purchase the vaccines and if a school Note: This is not the list of diseases for which immunizations are required as a con- district or local health department requests the vaccines and the dition of admission to an elementary, middle, junior high or senior high school or a local immunization effort is supervised by a physician.
    [Show full text]